These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26751841)

  • 1. The biology behind interleukin-6 targeted interventions.
    Liu X; Jones GW; Choy EH; Jones SA
    Curr Opin Rheumatol; 2016 Mar; 28(2):152-60. PubMed ID: 26751841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Interleukin-6 Signaling in Clinic.
    Kang S; Tanaka T; Narazaki M; Kishimoto T
    Immunity; 2019 Apr; 50(4):1007-1023. PubMed ID: 30995492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-6: from identification of the cytokine to development of targeted treatments.
    Assier E; Boissier MC; Dayer JM
    Joint Bone Spine; 2010 Dec; 77(6):532-6. PubMed ID: 20869898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
    Denton CP; Ong VH; Xu S; Chen-Harris H; Modrusan Z; Lafyatis R; Khanna D; Jahreis A; Siegel J; Sornasse T
    Ann Rheum Dis; 2018 Sep; 77(9):1362-1371. PubMed ID: 29853453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The biology and medical implications of interleukin-6.
    Tanaka T; Kishimoto T
    Cancer Immunol Res; 2014 Apr; 2(4):288-94. PubMed ID: 24764575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-6 blockade in ocular inflammatory diseases.
    Mesquida M; Leszczynska A; Llorenç V; Adán A
    Clin Exp Immunol; 2014 Jun; 176(3):301-9. PubMed ID: 24528300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting gp130 to prevent inflammation and promote insulin action.
    Kraakman MJ; Allen TL; Whitham M; Iliades P; Kammoun HL; Estevez E; Lancaster GI; Febbraio MA
    Diabetes Obes Metab; 2013 Sep; 15 Suppl 3():170-5. PubMed ID: 24003934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling.
    Hashizume M; Mihara M
    Rheumatol Int; 2009 Feb; 29(4):397-401. PubMed ID: 18802703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor α to gp130 expression: fusing experimental insights and dynamic modelling.
    Reeh H; Rudolph N; Billing U; Christen H; Streif S; Bullinger E; Schliemann-Bullinger M; Findeisen R; Schaper F; Huber HJ; Dittrich A
    Cell Commun Signal; 2019 May; 17(1):46. PubMed ID: 31101051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic uses of anti-interleukin-6 receptor antibody.
    Kang S; Tanaka T; Kishimoto T
    Int Immunol; 2015 Jan; 27(1):21-9. PubMed ID: 25142313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific inhibition of IL-6 signalling with monoclonal antibodies against the gp130 receptor.
    Liautard J; Sun RX; Cotte N; Gaillard JP; Mani JC; Klein B; Brochier J
    Cytokine; 1997 Apr; 9(4):233-41. PubMed ID: 9112331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade.
    Jordan SC; Choi J; Kim I; Wu G; Toyoda M; Shin B; Vo A
    Transplantation; 2017 Jan; 101(1):32-44. PubMed ID: 27547870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
    Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
    Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-6 and its receptors: a highly regulated and dynamic system.
    Wolf J; Rose-John S; Garbers C
    Cytokine; 2014 Nov; 70(1):11-20. PubMed ID: 24986424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the glycoprotein 130 receptor subunit to control pain and inflammation.
    Jazayeri JA; Upadhyay A; Vernallis AB; Carroll GJ
    J Interferon Cytokine Res; 2010 Dec; 30(12):865-73. PubMed ID: 20979530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
    Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
    Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-6: A Masterplayer in the Cytokine Network.
    Uciechowski P; Dempke WCM
    Oncology; 2020; 98(3):131-137. PubMed ID: 31958792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapeutic implication of IL-6 blockade.
    Tanaka T; Kishimoto T
    Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities.
    Kampan NC; Xiang SD; McNally OM; Stephens AN; Quinn MA; Plebanski M
    Curr Med Chem; 2018; 25(36):4785-4806. PubMed ID: 28707587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers.
    Ho LJ; Luo SF; Lai JH
    Biochem Pharmacol; 2015 Sep; 97(1):16-26. PubMed ID: 26080005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.